Ideas That Generate Results
Cancer Generics Market Analysis
Across the globe, oncology market, one of the fastest growing segments of pharmaceutical industry, has been expanding on back of rising cancer incidences, and hefty investment by private players. According to our latest research report, the global cancer generics market is anticipated to grow at a compound annual rate of around 26% during 2011-2015 as many anti-cancer blockbuster drugs are on the verge of patent expiry, and governments are introducing biogenerics for controlling rapidly increasing healthcare costs.
The research report, “Cancer Generics Market Analysis”, finds that the future holds tremendous potential as many drugs are under the development stage, and upon commercialization, they will boost the market in a significant manner. Our comprehensive report has effectively provided an insight into the global cancer generics market through proper analysis of drivers, restraints and key developments. The thorough study asserts that the players in the market have demonstrated their capabilities in terms of new launches and effective marketing.
On studying the market trends and drivers, we found that the US hospitals have reported a generic chemotherapy drug shortage in the recent times. The sharp rise in the number of ANDA and DMFs, especially in the oncology segment, by players from emerging countries is one of the successful instances that compliment the current status of the cancer generics market. Our in-depth study evaluates the current status and future potential of generic drugs in disease indications, such as lung cancer, breast cancer, colon cancer, stomach cancer and prostate cancer.
Our report covers all the key aspects of the global cancer generics market, including the competitive landscape that discusses profiles of leading players like Hospira and Accord Healthcare. A brief overview of oral and injectable generics has also been provided in the extensive study that aims at presenting an impartial picture of the market to clients.